Latest Breaking News On - கொலராடோ அண்சச்சுட்ஸ் மருத்துவ வளாகம் - Page 10 : comparemela.com
Submitted by [user:field first name]
DENVER – May 20, 2021 – A Colorado company with an innovative container system technology to help eliminate the spread of varroa mites and create optimal conditions in the winter for honeybees was among 36 Colorado start-ups approved for funding as part of the Colorado Office of Economic Development and International Trade (OEDIT)’s Advanced Industries Accelerator Grant Program. A total of $8,567,756 was approved this grant cycle for Proof-of-Concept and Early Stage Capital and Retention Grants to support Colorado’s advanced industries.
“As Colorado begins its recovery from the economic impact of the COVID-19 pandemic, support of the economic engines that are the advanced industries is more important than ever,” said Katie Woslager Senior Manager – Advanced Industries. “These projects expand the Colorado innovation ecosystem, creating jobs, expanding industries and driving investment into the state.
Fort-collins
Colorado
United-states
Wheat-ridge
Colorado-springs
Longmont
Boulder
Cherry-hills-village
Arvada
University-of-colorado-denver
David-wagner
Charlie-henry
Researchers develop new way to evaluate tuberculosis treatments 18 May, 2021
Gregory Robertson, an assistant professor in the Department of Microbiology, Immunology and Pathology at CSU, is one of the first authors on the study. He said that the effectiveness of tuberculosis treatments has been judged by studying tissue cultures from infected patients. Photo: John Eisele/CSU Photography
Tuberculosis, a disease caused by the bacterium
Mycobacterium tuberculosis, is a serious global health threat. The disease caused an estimated 1.5 million deaths in 2019 and current methods often fail to predict treatment outcomes in patients.
Nature Communications provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter treatment regimens. The research team was led by scientists at the University of Colorado Anschutz Medical Campus with Colorado State University’s Mycobacteria Research Laboratories
Carol-wilusz
Martin-voskuil
Payam-nahid
Gregory-robertson
Michelle-ramey
Anne-lenaerts
Nicholas-walter
Allison-bauman
Brendan-podell
Nature-communications
Department-of-microbiology
Share this article
Share this article
RARITAN, N.J., May 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO
® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO
® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiology s 70
Colorado
United-states
Americans
American
Marcp-bonaca
Jennifer-mcintyre
Lee-pasqualoni
Christopher-delorefice
Jennifer-silvent
American-heart-association
Division-of-cardiovascular-medicine
Janssen-pharmaceuticals-inc
vimarsana © 2020. All Rights Reserved.